Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
JAK inhibitors beat TNF inhibitors in the real world. A retrospective study of 390 ulcerative colitis patients found that JAK inhibitors were linked to significantly higher rates of steroid-free clinical remission and endoscopic healing at 52 weeks — even in patients who had already failed prior biologic therapies. Researchers say the findings support JAK inhibitors as a meaningful option in routine clinical practice.
JAK inhibitors are proving their worth beyond the clinical trial setting. A single-center retrospective study presented at the ACG Annual Scientific Meeting examined 390 ulcerative colitis (UC) patients treated with TNF inhibitors, vedolizumab, or JAK inhibitors between 2020 and 2025. Despite JAK inhibitor patients having greater baseline disease severity and higher rates of prior biologic exposure — factors that typically predict worse outcomes — they still came out ahead on nearly every measure.
The results were notable. JAK inhibitors were associated with significantly higher 52-week steroid-free clinical remission compared to TNF inhibitors, along with lower risks of treatment failure, steroid restarts, ED visits, and hospitalizations. Vedolizumab showed a positive but non-significant trend. Researchers were careful to frame the findings as associations rather than proof of superiority, given the study's retrospective design.
By the Numbers:
Why it matters: As UC treatment options expand, clinicians need real-world data to guide therapy selection — especially for patients with complex histories. This study suggests JAK inhibitors may deliver meaningful benefits even after prior biologic failure, helping inform treatment sequencing in everyday practice.
